Cargando…

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy

Three types of enzyme replacement therapies (ERTs) and two substrate reduction therapies (SRTs) are approved for symptomatic patients with type 1 Gaucher disease (GD1). Eliglustat is the second SRT approved, yet the first to be approved as first-line therapy for any adult patients with compatible CY...

Descripción completa

Detalles Bibliográficos
Autores principales:	Istaiti, Majdolen, Becker-Cohen, Michal, Dinur, Tama, Revel-Vilk, Shoshana, Zimran, Ari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659144/ https://www.ncbi.nlm.nih.gov/pubmed/36362492 http://dx.doi.org/10.3390/jcm11216265

Ejemplares similares

High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2023)

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
por: Dinur, Tama, et al.
Publicado: (2021)

Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
por: Dinur, Tama, et al.
Publicado: (2020)

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
por: Dinur, Tama, et al.
Publicado: (2022)

Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2019)

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease
por: Weill, Yishay, et al.
Publicado: (2020)

The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy
por: Zimran, Ari, et al.
Publicado: (2023)

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

A Deep-Learning Approach to Spleen Volume Estimation in Patients with Gaucher Disease
por: Azuri, Ido, et al.
Publicado: (2023)

A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease—Identifying Those at the Greatest Risk
por: Becker-Cohen, Michal, et al.
Publicado: (2022)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018)

Simultaneous Bilateral Femoral Osteonecrosis in Gaucher Disease
por: Cohen, Daniel, et al.
Publicado: (2023)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
por: Hughes, Derralynn A., et al.
Publicado: (2022)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Brain-Derived Neurotrophic Factor (BDNF) Is Associated with Platelet Activity and Bleeding Tendency in Patients with Gaucher Disease
por: Azoulay, David, et al.
Publicado: (2022)

Reply to Mistry et al. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on “Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158”
por: Hughes, Derralynn A., et al.
Publicado: (2023)

Anesthetic Approaches and Perioperative Complications of Total Hip Arthroplasty in Gaucher Disease: A Control-Matched Retrospective-Cohort Study
por: Grass, Ariel, et al.
Publicado: (2023)

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
por: Kamath, Ravi S., et al.
Publicado: (2014)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study
por: Revel-Vilk, Shoshana, et al.
Publicado: (2023)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Publicado: (2016)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
por: Kim, Yoo-Mi, et al.
Publicado: (2017)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
por: Bennett, Lunawati L, et al.
Publicado: (2015)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]
Publicado: (2015)

Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
por: Curado, Filipa, et al.
Publicado: (2023)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

P1633: LOW SERUM BDNF LEVELS ARE ASSOCIATED WITH LOWER PLATELETS’ CD62P REACTIVITY AND INCREASED BLEEDING TENDENCY IN PATIENTS WITH GAUCHER DISEASE
por: Azoulay, D., et al.
Publicado: (2022)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
por: Kleytman, Nathaniel, et al.
Publicado: (2021)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
por: Nalysnyk, Luba, et al.
Publicado: (2018)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat
por: Harai, Nozomi, et al.
Publicado: (2023)

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1
por: Vu, Lucie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mbf6asooei6s8c0se4410nhkgn